LimeLight of The week is

InMed Pharmaceuticals Inc.
(NASDAQ: INM)

InMed Pharmaceuticals Inc. (NASDAQ: INM) is a global leader in the development, manufacture and commercialization of rare cannabinoids for pharmaceutical and consumer health and wellness applications. InMed is a clinical stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids.

The company is dedicated to delivering new therapeutic alternatives to treat conditions with high unmet medical needs. The company is also developing a proprietary manufacturing technology to produce pharmaceutical-grade rare cannabinoids in the lab.

In October 2021, InMed announced its acquisition of BayMedica Inc., a private U.S. firm specializing in the manufacture and commercialization of rare cannabinoids for the health and wellness sector. BayMedica, now operating as a subsidiary of InMed, is a revenue-stage biotechnology firm leveraging its significant expertise in synthetic biology and pharmaceutical chemistry to develop efficient, scalable and proprietary manufacturing approaches to produce high quality, regulatory-compliant rare cannabinoids for consumer applications.

Investment Considerations

• InMed has a world class leadership team with a successful track record of drug development and commercialization.
• InMed has a solid and expanding intellectual property portfolio with multiple patents filed.
• The company recently acquired rare cannabinoids manufacturer BayMedica.
• InMed retains all commercial rights to its IntegraSyn manufacturing system.
• InMed has commenced a Phase 2 clinical trial of INM-755 (cannabinol) cream in epidermolysis bullosa.
• The consumer market for cannabinoid-based pharmaceuticals in the United States is forecast to grow to $25 billion by 2025 and to $50 billion by 2029.

Recent Coverage

InvestorNewsBreaks - InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Results of Peer-Reviewed Study Published in International Journal

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, has had its peer-reviewed scientific study published in the “International Journal of Molecular Sciences.” Titled “Effects of Rare Phytocannabinoids on the Endocannabinoid System of Human Keratinocytes,” the article reports on the study’s efforts to examine the biological activity of tetrahydrocannabivarin (“THCV”), cannabichromene (“CBC”) and other rare cannabinoids as well as the potential these substances have in addressing various skin conditions. The study used a recognized in vitro model of human keratinocytes to analyze how specific cannabinoids interacted with cannabinoid receptors and other endocannabinoid system components; the results indicate that each cannabinoid had distinct biological activity via the endocannabinoid system. The study was conducted in collaboration with Dr. Mauro Maccarrone, professor and chair of biochemistry at the Department of Biotechnological and Applied Clinical Sciences at the University of L’Aquila in Italy. “This peer-reviewed study provides important scientific research investigating the distinctly different physiological effects of rare cannabinoids,” said InMed Pharmaceuticals senior VP of preclinical research and development Dr. Eric Hsu in the press release. “As we continue to expand our portfolio of rare cannabinoids, including THCV and CBC, evidence-based research is imperative to improving our understanding of their biological activity. There is growing interest in the potential benefits of rare cannabinoids and this study represents InMed’s commitment to contributing to the body of research of rare cannabinoids.”

To view the report, visit https://ibn.fm/3Uy2n

To view the full source article, visit: THIS LINK

Receive SMS Text Alerts from CannabisNewsWire

Text "Cannabis" to 844-397-5787

(US Mobile Phones Only)

Featured Event

Grow Up Conference
9/12 - 9/14 – Niagara Falls, ON

Join us in spectacular Niagara Falls, ON for 3 days of cannabis cultivation and extraction.

Join top growers, suppliers, manufacturers, extraction equipment/services, hundreds of top speakers/keynotes and thousands of delegates together to bring you up-to-date on proven methods, innovations and technology. This year’s expo will include the Grow Up Extraction Zone.

Learn from over 100 cannabis cultivation and extraction experts at our 3 day conference.

Grow Up Conference and Expo is focused on the education, collaboration and growth of the cannabis growing industry. Meet licensed producers, suppliers, equipment manufacturers, investors, lawyers, government officials and growing enthusiasts – all in one magnificent location.

Meet old friends and create new relationships at Grow Up's famous Meet the Exhibitors networking party.

Upcoming Events

• NECANN’s New Jersey Convention — Atlantic City, NJ — 10/1 - 10/2
• NECANN's Maine Convention — Portland, ME — 10/15 - 10/16
• Alternative Products Expo, Chicago — Chicago — 11/3 - 11/5

About CannabisNewsWire (CNW)

CannabisNewsWire (CNW) is a multifaceted financial news and publishing company that delivers a new generation of social communication solutions, news aggregation and syndication, and enhanced news release services. Leveraging a professional team of journalists and writers, CNW introduces private and public companies to a wide audience of investors, consumers, journalists and the general public via social media and a rapidly expanding network of over 5,000 key distribution outlets. Cutting through information overload, CNW's innovative and proprietary systems clearly and succinctly deliver its clients much needed visibility, recognition and brand awareness. CNW is where news, content and information converge.